In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without ...

Palobiofarma Partners with Flex Databases for Advanced Pharmacovigilance ManagementFebruary 6, 2025Palobiofarma, a leading ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

The Global Coalition for Adaptive Research (GCAR) today announced that they are collaborating with Operational Medical ...

Independent research institute BioMed X has completed its oncology research project in partnership with Merck, the data from ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities. Recruitment will commence at leading U.S. trial sites, with the potential ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM syndr ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...

The BornToGetThere project has been set to advance early detection, surveillance, and intervention for infants at high risk ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.